60 Degrees Pharmaceuticals Reports Insights from Q2 2025
Recently, 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP) has shared its financial results for the second quarter of 2025. This quarter experienced some interesting dynamics due to a supply disruption which impacted product revenues, yet ultimately resulted in higher profitability. The Company has showcased resilience through adopting a cash-pay distribution model, leading to positive financial outcomes.
Behavioral Changes Amid Supply Disruptions
The second quarter of 2025 saw net product revenue decline, primarily due to resolved supply chain disruptions, which affected commercial pharmacy deliveries of ARAKODA. Despite the revenue drop, profitability improved as more cash-pay patients turned to KODATEF (tafenoquine), demonstrating a shift in purchasing behavior amidst these challenges.
Financial Positioning
At the end of the second quarter, 60 Degrees Pharmaceuticals reported $1.97 million in cash reserves, which is projected to sustain operations through early 2026. This significant financial positioning is crucial as they navigate through ongoing market conditions while preparing for a busy tick season.
Business Analytics and Projections
For the current quarter, the Company also projected a continuation of their strategic focus on profitable avenues. They displayed a cash runway that ensures ongoing operations and progressive steps toward clinical trials aimed at conditions like babesiosis if certain milestones are met.
Financial Performance Analysis
Here are the key financial highlights from their performance in the second quarter of 2025, emphasizing significant changes since the previous year:
- Net product revenues experienced a 19% decrease year-over-year, dropping from $125 thousand to $101 thousand. This was attributed to a decline in ARAKODA pharmacy deliveries, highlighting an impactful supply chain disruption.
- Gross profits saw a notable increase to approximately $51 thousand compared to $35 thousand from the previous year, which reflects improved sales effective due to lower overall cost of sales.
- Operating expenses were substantially reduced to around $1.86 million, a significant drop from approximately $4.22 million, mainly due to the absence of considerable non-cash research and development costs that affected past quarters.
- The net loss attributable to common shareholders was approximately $1.84 million, equating to ($1.25) per share, a substantial decrease from $4.29 million or ($21.12) per share reported in Q2 2024.
- Future financial projections suggest that with internal sales metrics and ongoing cash flow from recent funding, the company maintains a solid foothold that anticipates financial viability extending to March 31, 2026.
Business Highlights for Q2 2025
Strategically, the Company made notable advances during this quarter:
- Completion of several commercial research studies indicating that the annual incidence of babesiosis ranges between 25,000 and 380,000 cases. This insight suggests a vast market opportunity for ARAKODA, approximating a total addressable market of $1.1 billion over the next decade.
- A new 8-count ARAKODA bottle format was introduced, aimed at reducing costs for short-term travelers entering malaria-endemic regions.
About 60 Degrees Pharmaceuticals, Inc.
Founded in 2010, 60 Degrees Pharmaceuticals, Inc. concentrates on developing innovative medicines for infectious diseases. With the FDA approval of ARAKODA (tafenoquine) in 2018, they've solidified their commitment to improving health outcomes for millions. Collaborating with prestigious research institutions globally, the Company continually seeks to expand its impact through groundbreaking research supported by various funding sources.
Media Contact:
Sheila A. Burke
SheilaBurke-consultant@60degreespharma.com
(484) 667-6330
Investor Contact:
Patrick Gaynes
patrickgaynes@60degreespharma.com
(310) 989-5666
Frequently Asked Questions
What were the main reasons for the revenue decline in Q2 2025?
The decline was primarily a result of a supply disruption that affected pharmacy deliveries of ARAKODA, coupled with shifts in purchasing behaviors.
How did the company's profitability change?
While revenues decreased, profitability increased due to a rise in cash-pay patients and improved gross margins from KODATEF sales.
What is the expected cash runway for 60 Degrees Pharmaceuticals?
With cash reserves of $1.97 million and recent funding, the company expects to sustain operations until at least March 31, 2026.
What market potential does ARAKODA have?
Research suggests that ARAKODA may address an annual incidence of up to 380,000 babesiosis cases, representing a potential market of approximately $1.1 billion.
What new products were launched during the quarter?
An 8-count bottle format of ARAKODA was introduced, specially designed to cater to short-term travelers.
